AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

ARF-BP1 as mediator of p53 dependent and independent tumor suppression

Technology Benefits: A novel target for cancer therapy ARF has tumor suppressor activity that is p53 independent Since ARF-BP1 interacts with ARF and p53 but not with Mdm2, it is a useful therapeutic target in tumors that lack Mdm2 activity

Technology Application: Assay for compounds that inhibit ARF-BP1 binding to p53 Inhibitors of ARF-BP1 binding to p53 can be further developed into potential broad spectrum cancer drugs Determination of ARF-BP1 status of tumors may have prognostic value where the cellular level of ARF-BP1 may inversely correlate with good prognosis ARF-BP1 could be used as a biomarker for pre-malignant tumors or for tumor staging and grading

Detailed Technology Description: The present invention identifies ARF-BP1, a novel ubiquitin ligase, as a critical mediator of p53- dependent and p53-independent tumor suppression functions of ARF. ARF-BP1 directly binds and ubiquitinates p53. Inactivation of ARF-BP1 stabilizes p53 ...

*Abstract: None

*Inquiry: Cynthia LangColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR: 1694

*Principal Investigator

*Publications: ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor. D. Chen et. al, Cell, (2005) Volume 121, Issue 7, Pages 1071-1083.

*Web Links: USPTO: US 7,358,335

Country/Region: USA

For more information, please click Here